Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), was evaluated in a randomized, double-blind, placebo-controlled trial for the treatment of fistulas in patients with Crohn's disease. The study included 94 adults with draining abdominal or perianal fistulas lasting at least three months. Patients were randomly assigned to receive placebo (n=31), 5 mg/kg infliximab (n=31), or 10 mg/kg infliximab (n=32), administered intravenously at weeks 0, 2, and 6. The primary endpoint was a 50% or greater reduction in the number of draining fistulas observed at two or more consecutive visits. Secondary endpoints included fistula closure and changes in disease activity scores. Results showed that 68% of patients receiving 5 mg/kg infliximab and 56% of those receiving 10 mg/kg achieved the primary endpoint, compared to 26% in the placebo group (P=0.002 and P=0.02, respectively). Additionally, 55% of 5 mg/kg patients and 38% of 10 mg/kg patients had complete fistula closure, compared to 13% in the placebo group (P=0.001 and P=0.04, respectively). The median time for fistulas to remain closed was three months. Adverse events occurred in over 60% of patients, with the most common being headache, abscess, upper respiratory tract infection, and fatigue. Infliximab was effective in reducing fistulas and improving disease activity scores, with no significant difference in efficacy between the two infliximab doses. The 5 mg/kg dose showed similar efficacy to the 10 mg/kg dose. Safety was generally acceptable, with no deaths reported. Infliximab was well-tolerated, and adverse events were not dose-related. The study supports the use of infliximab for treating fistulas in Crohn's disease, with an initial dose of 5 mg/kg followed by doses at weeks 2 and 6. The results indicate that infliximab is an effective treatment for fistulas in patients with Crohn's disease.Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), was evaluated in a randomized, double-blind, placebo-controlled trial for the treatment of fistulas in patients with Crohn's disease. The study included 94 adults with draining abdominal or perianal fistulas lasting at least three months. Patients were randomly assigned to receive placebo (n=31), 5 mg/kg infliximab (n=31), or 10 mg/kg infliximab (n=32), administered intravenously at weeks 0, 2, and 6. The primary endpoint was a 50% or greater reduction in the number of draining fistulas observed at two or more consecutive visits. Secondary endpoints included fistula closure and changes in disease activity scores. Results showed that 68% of patients receiving 5 mg/kg infliximab and 56% of those receiving 10 mg/kg achieved the primary endpoint, compared to 26% in the placebo group (P=0.002 and P=0.02, respectively). Additionally, 55% of 5 mg/kg patients and 38% of 10 mg/kg patients had complete fistula closure, compared to 13% in the placebo group (P=0.001 and P=0.04, respectively). The median time for fistulas to remain closed was three months. Adverse events occurred in over 60% of patients, with the most common being headache, abscess, upper respiratory tract infection, and fatigue. Infliximab was effective in reducing fistulas and improving disease activity scores, with no significant difference in efficacy between the two infliximab doses. The 5 mg/kg dose showed similar efficacy to the 10 mg/kg dose. Safety was generally acceptable, with no deaths reported. Infliximab was well-tolerated, and adverse events were not dose-related. The study supports the use of infliximab for treating fistulas in Crohn's disease, with an initial dose of 5 mg/kg followed by doses at weeks 2 and 6. The results indicate that infliximab is an effective treatment for fistulas in patients with Crohn's disease.